GMABGenmabRunning, no new patients
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,095 (final count)
- Started
- Feb 5, 2024
- Main results expected
- Nov 2037
- Fully finished
- Nov 2037
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)
Measured over: Up to 30 Months
Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)
Measured over: Up to 10 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06191744 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC